BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Targher G, Bertolini L, Rodella S, Zoppini G, Lippi G, Day C, Muggeo M. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia. 2008;51:444-450. [PMID: 18058083 DOI: 10.1007/s00125-007-0897-4] [Cited by in Crossref: 198] [Cited by in F6Publishing: 174] [Article Influence: 13.2] [Reference Citation Analysis]
Number Citing Articles
1 Arman T, Lynch KD, Goedken M, Clarke JD. Sub-chronic microcystin-LR renal toxicity in rats fed a high fat/high cholesterol diet. Chemosphere 2021;269:128773. [PMID: 33143886 DOI: 10.1016/j.chemosphere.2020.128773] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Marcuccilli M, Chonchol M. NAFLD and Chronic Kidney Disease. Int J Mol Sci. 2016;17:562. [PMID: 27089331 DOI: 10.3390/ijms17040562] [Cited by in Crossref: 64] [Cited by in F6Publishing: 60] [Article Influence: 10.7] [Reference Citation Analysis]
3 Wen X, Zhou X, Chen D, Cheng J, Ji L. Association between non-alcoholic fatty liver disease and diabetes-related microvascular complications: A retrospective cross-sectional study of hospitalized patients. Endocr Pract 2021:S1530-891X(21)00046-X. [PMID: 33601024 DOI: 10.1016/j.eprac.2021.02.004] [Reference Citation Analysis]
4 Targher G, Bertolini L, Padovani R, Rodella S, Zoppini G, Pichiri I, Sorgato C, Zenari L, Bonora E. Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes. J Hepatol 2010;53:713-8. [PMID: 20619918 DOI: 10.1016/j.jhep.2010.04.030] [Cited by in Crossref: 138] [Cited by in F6Publishing: 131] [Article Influence: 11.5] [Reference Citation Analysis]
5 Yeung MW, Wong GL, Choi KC, Luk AO, Kwok R, Shu SS, Chan AW, Lau ESH, Ma RCW, Chan HL, Chan JC, Wong VW, Kong AP. Advanced liver fibrosis but not steatosis is independently associated with albuminuria in Chinese patients with type 2 diabetes. J Hepatol. 2017;. [PMID: 28989092 DOI: 10.1016/j.jhep.2017.09.020] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
6 Jung C, Lee B, Choi D, Jung S, Kim B, Kim C, Kang S, Mok J. Association of grade of non-alcoholic fatty liver disease and glycated albumin to glycated hemoglobin ratio in patients with type 2 diabetes mellitus. Diabetes Research and Clinical Practice 2017;125:53-61. [DOI: 10.1016/j.diabres.2016.12.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
7 Szymanska M, Mahmood D, Yap TE, Cordeiro MF. Recent Advancements in the Medical Treatment of Diabetic Retinal Disease. Int J Mol Sci 2021;22:9441. [PMID: 34502350 DOI: 10.3390/ijms22179441] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Saito H, Tanabe H, Kudo A, Machii N, Higa M, Yamaguchi S, Maimaituxun G, Abe K, Takahashi A, Tanaka K, Asahi K, Masuzaki H, Ohira H, Kazama JJ, Shimabukuro M. High FIB4 index is an independent risk factor of diabetic kidney disease in type 2 diabetes. Sci Rep 2021;11:11753. [PMID: 34083571 DOI: 10.1038/s41598-021-88285-6] [Reference Citation Analysis]
9 Mastrocola R, Collino M, Rogazzo M, Medana C, Nigro D, Boccuzzi G, Aragno M. Advanced glycation end products promote hepatosteatosis by interfering with SCAP-SREBP pathway in fructose-drinking mice. Am J Physiol Gastrointest Liver Physiol. 2013;305:G398-G407. [PMID: 23868406 DOI: 10.1152/ajpgi.00450.2012] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 4.4] [Reference Citation Analysis]
10 Ballestri S, Mantovani A, Nascimbeni F, Lugari S, Lonardo A. Extra-hepatic manifestations and complications of nonalcoholic fatty liver disease. Future Med Chem 2019;11:2171-92. [PMID: 31538528 DOI: 10.4155/fmc-2019-0003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
11 Dufour JF, Caussy C, Loomba R. Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges. Gut 2020;69:1877-84. [PMID: 32381514 DOI: 10.1136/gutjnl-2019-319104] [Cited by in Crossref: 34] [Cited by in F6Publishing: 23] [Article Influence: 17.0] [Reference Citation Analysis]
12 Chung GE, Cho EJ, Yoo JJ, Chang Y, Cho Y, Park SH, Shin DW, Han K, Yu SJ. Nonalcoholic fatty liver disease is associated with the development of obstructive sleep apnea. Sci Rep 2021;11:13473. [PMID: 34188101 DOI: 10.1038/s41598-021-92703-0] [Reference Citation Analysis]
13 Zhang J, Zhang B, Cheng Y, Xu J. Low serum CTRP3 levels are associated with nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. Cytokine 2018;106:131-5. [DOI: 10.1016/j.cyto.2017.10.023] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
14 Serra-planas E, Aguilera E, Castro L, Rodríguez R, Salinas I, Lucas A, Joaquín C, Puig R, Mauricio D, Puig-domingo M. Low prevalence of non-alcoholic fatty liver disease in patients with type 1 diabetes is associated with decreased subclinical cardiovascular disease: 在1型糖尿病患者中非酒精性脂肪性肝病的患病率较低与亚临床心血管疾病较少相关. Journal of Diabetes 2017;9:1065-72. [DOI: 10.1111/1753-0407.12539] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
15 Koebnick C, Getahun D, Reynolds K, Coleman KJ, Porter AH, Lawrence JM, Punyanitya M, Quinn VP, Jacobsen SJ. Trends in Nonalcoholic Fatty Liver Disease–related Hospitalizations in US Children, Adolescents, and Young Adults. Journal of Pediatric Gastroenterology & Nutrition 2009;48:597-603. [DOI: 10.1097/mpg.0b013e318192d224] [Cited by in Crossref: 21] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
16 Hwang ST, Cho YK, Yun JW, Park JH, Kim HJ, Park DI, Sohn CI, Jeon WK, Kim BI, Rhee EJ. Impact of non-alcoholic fatty liver disease on microalbuminuria in patients with prediabetes and diabetes. Intern Med J. 2010;40:437-442. [PMID: 19460054 DOI: 10.1111/j.1445-5994.2009.01979.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 5.0] [Reference Citation Analysis]
17 Lottenberg AM, Afonso Mda S, Lavrador MS, Machado RM, Nakandakare ER. The role of dietary fatty acids in the pathology of metabolic syndrome. J Nutr Biochem 2012;23:1027-40. [PMID: 22749135 DOI: 10.1016/j.jnutbio.2012.03.004] [Cited by in Crossref: 125] [Cited by in F6Publishing: 109] [Article Influence: 12.5] [Reference Citation Analysis]
18 Targher G, Lonardo A, Byrne CD. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. Nat Rev Endocrinol 2018;14:99-114. [DOI: 10.1038/nrendo.2017.173] [Cited by in Crossref: 142] [Cited by in F6Publishing: 122] [Article Influence: 28.4] [Reference Citation Analysis]
19 Chinnadurai R, Ritchie J, Green D, Kalra PA. Non-alcoholic fatty liver disease and clinical outcomes in chronic kidney disease. Nephrology Dialysis Transplantation 2019;34:449-57. [DOI: 10.1093/ndt/gfx381] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
20 Rittig K, Hieronimus A, Thamer C, Machann J, Peter A, Stock J, Schick F, Fritsche A, Stefan N, Häring H, Balletshofer B. Reducing visceral adipose tissue mass is essential for improving endothelial function in type 2 diabetes prone individuals. Atherosclerosis 2010;212:575-9. [DOI: 10.1016/j.atherosclerosis.2010.06.042] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
21 Khandelwal R, Dassanayake AS, Conjeevaram HS, Singh SP. Non-alcoholic fatty liver disease in diabetes: When to refer to the hepatologist? World J Diabetes 2021; 12(9): 1479-1493 [PMID: 34630901 DOI: 10.4239/wjd.v12.i9.1479] [Reference Citation Analysis]
22 Catalano D, Trovato GM, Martines GF, Pirri C, Trovato FM. Renal function and severity of bright liver. Relationship with insulin resistance, intrarenal resistive index, and glomerular filtration rate. Hepatol Int. 2011;5:822-829. [PMID: 21484130 DOI: 10.1007/s12072-011-9254-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
23 Valenti L, Bugianesi E, Pajvani U, Targher G. Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes? Liver Int 2016;36:1563-79. [DOI: 10.1111/liv.13185] [Cited by in Crossref: 85] [Cited by in F6Publishing: 79] [Article Influence: 14.2] [Reference Citation Analysis]
24 Xu C, Yu C, Ma H, Xu L, Miao M, Li Y. Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population: the Zhejiang Zhenhai Study. Am J Gastroenterol. 2013;108:1299-1304. [PMID: 23567356 DOI: 10.1038/ajg.2013.104] [Cited by in Crossref: 97] [Cited by in F6Publishing: 92] [Article Influence: 10.8] [Reference Citation Analysis]
25 Niu Y, Zhang W, Zhang H, Li X, Lin N, Su W, Gu H, Zhu L, Fan J, Qin L, Yang Z, Su Q. Serum creatinine levels and risk of nonalcohol fatty liver disease in a middle-aged and older Chinese population: A cross-sectional analysis. Diabetes Metab Res Rev 2021;:e3489. [PMID: 34344058 DOI: 10.1002/dmrr.3489] [Reference Citation Analysis]
26 Fisher CD, Lickteig AJ, Augustine LM, Ranger-Moore J, Jackson JP, Ferguson SS, Cherrington NJ. Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metab Dispos 2009;37:2087-94. [PMID: 19651758 DOI: 10.1124/dmd.109.027466] [Cited by in Crossref: 188] [Cited by in F6Publishing: 184] [Article Influence: 14.5] [Reference Citation Analysis]
27 Bica C, Sandu C, Suceveanu AI, Sarbu E, Stoica RA, Gherghiceanu F, Bohiltea RE, Stefan SD, Stoian AP. Non-alcoholic fatty liver disease: A major challenge in type 2 diabetes mellitus (Review). Exp Ther Med 2020;20:2387-91. [PMID: 32765720 DOI: 10.3892/etm.2020.8882] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
28 Chen G, Ni Y, Nagata N, Xu L, Ota T. Micronutrient Antioxidants and Nonalcoholic Fatty Liver Disease. Int J Mol Sci. 2016;17:1379. [PMID: 27563875 DOI: 10.3390/ijms17091379] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 4.5] [Reference Citation Analysis]
29 Sesti G, Fiorentino TV, Arturi F, Perticone M, Sciacqua A, Perticone F. Association between noninvasive fibrosis markers and chronic kidney disease among adults with nonalcoholic fatty liver disease. PLoS One. 2014;9:e88569. [PMID: 24520400 DOI: 10.1371/journal.pone.0088569] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
30 Gerstein HC, Werstuck GH. Dysglycaemia, vasculopenia, and the chronic consequences of diabetes. The Lancet Diabetes & Endocrinology 2013;1:71-8. [DOI: 10.1016/s2213-8587(13)70025-1] [Cited by in Crossref: 28] [Cited by in F6Publishing: 10] [Article Influence: 3.1] [Reference Citation Analysis]
31 Byrne CD, Targher G. NAFLD as a driver of chronic kidney disease. J Hepatol. 2020;72:785-801. [PMID: 32059982 DOI: 10.1016/j.jhep.2020.01.013] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 28.0] [Reference Citation Analysis]
32 Mantovani A, Zusi C, Dalbeni A, Grani G, Buzzetti E. Risk of Kidney Dysfunction IN Nafld. CPD 2020;26:1045-61. [DOI: 10.2174/1381612825666191026113119] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
33 Fargion S, Porzio M, Fracanzani AL. Nonalcoholic fatty liver disease and vascular disease: State-of-the-art. World J Gastroenterol 2014; 20(37): 13306-13324 [PMID: 25309067 DOI: 10.3748/wjg.v20.i37.13306] [Cited by in CrossRef: 118] [Cited by in F6Publishing: 116] [Article Influence: 14.8] [Reference Citation Analysis]
34 Zhang J, Li K, Pan L, Teng F, Zhang P, Lin B, Yuan Y, Wei X, Li W, Zhang H. Association of circulating adipsin with nonalcoholic fatty liver disease in obese adults: a cross-sectional study. BMC Gastroenterol 2021;21:131. [PMID: 33743586 DOI: 10.1186/s12876-021-01721-9] [Reference Citation Analysis]
35 Cigrovski Berkovic M, Virovic-Jukic L, Bilic-Curcic I, Mrzljak A. Post-transplant diabetes mellitus and preexisting liver disease - a bidirectional relationship affecting treatment and management. World J Gastroenterol 2020; 26(21): 2740-2757 [PMID: 32550751 DOI: 10.3748/wjg.v26.i21.2740] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
36 Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 2017;14:32-42. [PMID: 27729660 DOI: 10.1038/nrgastro.2016.147] [Cited by in Crossref: 329] [Cited by in F6Publishing: 309] [Article Influence: 54.8] [Reference Citation Analysis]
37 Cuthbertson DJ, Irwin A, Gardner CJ, Daousi C, Purewal T, Furlong N, Goenka N, Thomas EL, Adams VL, Pushpakom SP, Pirmohamed M, Kemp GJ. Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists. PLoS One. 2012;7:e50117. [PMID: 23236362 DOI: 10.1371/journal.pone.0050117] [Cited by in Crossref: 138] [Cited by in F6Publishing: 134] [Article Influence: 13.8] [Reference Citation Analysis]
38 Mantovani A, Turino T, Lando MG, Gjini K, Byrne CD, Zusi C, Ravaioli F, Colecchia A, Maffeis C, Salvagno G, Lippi G, Bonora E, Targher G. Screening for non-alcoholic fatty liver disease using liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetes. Diabetes Metab. 2019;. [PMID: 31786361 DOI: 10.1016/j.diabet.2019.11.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
39 Xia MF, Bian H, Gao X. NAFLD and Diabetes: Two Sides of the Same Coin? Rationale for Gene-Based Personalized NAFLD Treatment. Front Pharmacol. 2019;10:877. [PMID: 31447675 DOI: 10.3389/fphar.2019.00877] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 9.3] [Reference Citation Analysis]
40 Jenks SJ, Conway BR, Hor TJ, Williamson RM, Mclachlan S, Robertson C, Morling JR, Strachan MWJ, Price JF. Hepatic steatosis and non-alcoholic fatty liver disease are not associated with decline in renal function in people with Type 2 diabetes. Diabet Med 2014;31:1039-46. [DOI: 10.1111/dme.12456] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
41 Ziegler D, Strom A, Kupriyanova Y, Bierwagen A, Bönhof GJ, Bódis K, Müssig K, Szendroedi J, Bobrov P, Markgraf DF, Hwang JH, Roden M; GDS Group. Association of Lower Cardiovagal Tone and Baroreflex Sensitivity With Higher Liver Fat Content Early in Type 2 Diabetes.J Clin Endocrinol Metab. 2018;103:1130-1138. [PMID: 29267946 DOI: 10.1210/jc.2017-02294] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
42 Yan LH, Mu B, Guan Y, Liu X, Zhao N, Pan D, Wang SZ. Assessment of the relationship between non-alcoholic fatty liver disease and diabetic complications. J Diabetes Investig 2016;7:889-94. [PMID: 27181828 DOI: 10.1111/jdi.12518] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
43 Ciardullo S, Muraca E, Perra S, Bianconi E, Zerbini F, Oltolini A, Cannistraci R, Parmeggiani P, Manzoni G, Gastaldelli A, Lattuada G, Perseghin G. Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications. BMJ Open Diabetes Res Care. 2020;8. [PMID: 32049637 DOI: 10.1136/bmjdrc-2019-000904] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 19.0] [Reference Citation Analysis]
44 Bril F, Cusi K. Nonalcoholic Fatty Liver Disease: The New Complication of Type 2 Diabetes Mellitus. Endocrinol Metab Clin North Am 2016;45:765-81. [PMID: 27823604 DOI: 10.1016/j.ecl.2016.06.005] [Cited by in Crossref: 65] [Cited by in F6Publishing: 58] [Article Influence: 10.8] [Reference Citation Analysis]
45 Shah RV, Allison MA, Lima JA, Abbasi SA, Mongraw-Chaffin M, Jerosch-Herold M, Ding J, Budoff MJ, Murthy VL. Liver steatosis and the risk of albuminuria: the multi-ethnic study of atherosclerosis. J Nephrol 2015;28:577-84. [PMID: 25712234 DOI: 10.1007/s40620-015-0177-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
46 Jung CY, Ryu GW, Kim HW, Ahn SH, Kim SU, Kim BS. Advanced liver fibrosis measured by transient elastography predicts chronic kidney disease development in individuals with non-alcoholic fatty liver disease. Diabetologia 2021. [PMID: 34932136 DOI: 10.1007/s00125-021-05627-9] [Reference Citation Analysis]
47 Pardina E, Peinado-Onsurbe J. [Adolescence, obesity, and the role of lipoprotein lipases in the non-alcoholic fatty liver disease]. Endocrinol Nutr. 2012;59:343-345. [PMID: 22658542 DOI: 10.1016/j.endonu.2012.03.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
48 Alam U. To Be, or Not To Be … a Biomarker? A Question to the FDA. Clin Ther 2021;43:1438-40. [PMID: 34535276 DOI: 10.1016/j.clinthera.2021.08.010] [Reference Citation Analysis]
49 Barchetta I, Cimini FA, Leonetti F, Capoccia D, Di Cristofano C, Silecchia G, Orho-melander M, Melander O, Cavallo MG. Increased Plasma Proneurotensin Levels Identify NAFLD in Adults With and Without Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism 2018;103:2253-60. [DOI: 10.1210/jc.2017-02751] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
50 Pan L, Zhang H, Huang Z, Sun Q, Chen Z, Li Z, Yang S, Li X, Li X. Intrahepatic triglyceride content is independently associated with chronic kidney disease in obese adults: A cross-sectional study. Metabolism 2015;64:1077-85. [DOI: 10.1016/j.metabol.2015.06.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
51 Jang HR, Kang D, Sinn DH, Gu S, Cho SJ, Lee JE, Huh W, Paik SW, Ryu S, Chang Y, Shafi T, Lazo M, Guallar E, Cho J, Gwak GY. Nonalcoholic fatty liver disease accelerates kidney function decline in patients with chronic kidney disease: a cohort study. Sci Rep. 2018;8:4718. [PMID: 29549269 DOI: 10.1038/s41598-018-23014-0] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 8.5] [Reference Citation Analysis]
52 Reccia I, Kumar J, Akladios C, Virdis F, Pai M, Habib N, Spalding D. Non-alcoholic fatty liver disease: A sign of systemic disease. Metabolism. 2017;72:94-108. [PMID: 28641788 DOI: 10.1016/j.metabol.2017.04.011] [Cited by in Crossref: 85] [Cited by in F6Publishing: 81] [Article Influence: 17.0] [Reference Citation Analysis]
53 Sharma P, Sun Y, Neal J, Erley J, Shen J, Tischer S, Sonnenday CJ, Park JM. Renal Outcomes of Liver Transplantation Recipients Receiving Standard Immunosuppression and Early Renal Sparing Immunosuppression: A Retrospective Single Center Study. Transplant Direct 2019;5:e480. [PMID: 31579808 DOI: 10.1097/TXD.0000000000000917] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
54 Leite NC, Villela-Nogueira CA, Pannain VL, Bottino AC, Rezende GF, Cardoso CR, Salles GF. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors. Liver Int. 2011;31:700-706. [PMID: 21457442 DOI: 10.1111/j.1478-3231.2011.02482.x] [Cited by in Crossref: 98] [Cited by in F6Publishing: 97] [Article Influence: 8.9] [Reference Citation Analysis]
55 Armstrong MJ, Hazlehurst JM, Parker R, Koushiappi E, Mann J, Khan S, Philips A, Chandler L, Johnson J, Round M, Haydon G, Karamat MA, Newsome PN, Tomlinson JW. Severe asymptomatic non-alcoholic fatty liver disease in routine diabetes care; a multi-disciplinary team approach to diagnosis and management. QJM 2014;107:33-41. [PMID: 24131545 DOI: 10.1093/qjmed/hct198] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
56 Huang X, Xu M, Chen Y, Peng K, Huang Y, Wang P, Ding L, Lin L, Xu Y, Chen Y, Lu J, Wang W, Bi Y, Ning G. Validation of the Fatty Liver Index for Nonalcoholic Fatty Liver Disease in Middle-Aged and Elderly Chinese. Medicine (Baltimore) 2015;94:e1682. [PMID: 26448014 DOI: 10.1097/MD.0000000000001682] [Cited by in Crossref: 59] [Cited by in F6Publishing: 29] [Article Influence: 9.8] [Reference Citation Analysis]
57 Wilechansky RM, Pedley A, Massaro JM, Hoffmann U, Benjamin EJ, Long MT. Relations of liver fat with prevalent and incident chronic kidney disease in the Framingham Heart Study: A secondary analysis. Liver Int 2019;39:1535-44. [PMID: 31033142 DOI: 10.1111/liv.14125] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
58 Hamed AE, Elsahar M, Elwan NM, El-nakeep S, Naguib M, Soliman HH, Ahmed Aboubakr A, Abdelmaqsod A, Sedrak H, Assaad SN, Elwakil R, Esmat G, Salh S, Mostafa T, Mogawer S, Sadek SE, Saber MM, Ezelarab H, Mahmoud AA, Sultan S, El Kassas M, Kamal E, Elsayed NM, moussa S. Managing diabetes and liver disease association. Arab Journal of Gastroenterology 2018;19:166-79. [DOI: 10.1016/j.ajg.2018.08.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
59 VanWagner LB, Rinella ME. Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease. Curr Hepatol Rep. 2016;15:75-85. [PMID: 27218012 DOI: 10.1007/s11901-016-0295-9] [Cited by in Crossref: 57] [Cited by in F6Publishing: 51] [Article Influence: 9.5] [Reference Citation Analysis]
60 Kim K, Oh TJ, Cho HC, Lee YK, Ahn CH, Koo BK, Moon JH, Choi SH, Jang HC. Liver fibrosis indices are related to diabetic peripheral neuropathy in individuals with type 2 diabetes. Sci Rep 2021;11:24372. [PMID: 34934162 DOI: 10.1038/s41598-021-03870-z] [Reference Citation Analysis]
61 Non-alcoholic Fatty Liver Disease Study Group, Lonardo A, Bellentani S, Argo CK, Ballestri S, Byrne CD, Caldwell SH, Cortez-Pinto H, Grieco A, Machado MV, Miele L, Targher G. Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. Dig Liver Dis. 2015;47:997-1006. [PMID: 26454786 DOI: 10.1016/j.dld.2015.08.004] [Cited by in Crossref: 246] [Cited by in F6Publishing: 224] [Article Influence: 35.1] [Reference Citation Analysis]
62 Byrne CD, Olufadi R, Bruce KD, Cagampang FR, Ahmed MH. Metabolic disturbances in non-alcoholic fatty liver disease. Clin Sci (Lond). 2009;116:539-564. [PMID: 19243311 DOI: 10.1042/cs20080253] [Cited by in Crossref: 160] [Cited by in F6Publishing: 74] [Article Influence: 12.3] [Reference Citation Analysis]
63 Li AA, Ahmed A, Kim D. Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease. Gut Liver. 2020;14:168-178. [PMID: 31195434 DOI: 10.5009/gnl19069] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 21.0] [Reference Citation Analysis]
64 Bang KB, Cho YK. Comorbidities and Metabolic Derangement of NAFLD. J Lifestyle Med. 2015;5:7-13. [PMID: 26528424 DOI: 10.15280/jlm.2015.5.1.7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
65 Jia G, Di F, Wang Q, Shao J, Gao L, Wang L, Li Q, Li N. Non-Alcoholic Fatty Liver Disease Is a Risk Factor for the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus. PLoS One. 2015;10:e0142808. [PMID: 26566287 DOI: 10.1371/journal.pone.0142808] [Cited by in Crossref: 37] [Cited by in F6Publishing: 43] [Article Influence: 5.3] [Reference Citation Analysis]
66 Mbata O, Abo El-Magd NF, El-Remessy AB. Obesity, metabolic syndrome and diabetic retinopathy: Beyond hyperglycemia. World J Diabetes 2017; 8(7): 317-329 [PMID: 28751954 DOI: 10.4239/wjd.v8.i7.317] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
67 Li G, Shi W, Hug H, Chen Y, Liu L, Yin D. Nonalcoholic fatty liver disease associated with impairment of kidney function in nondiabetes population. Biochem Med (Zagreb). 2012;22:92-99. [PMID: 22384523 DOI: 10.11613/bm.2012.010] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
68 Mężyńska M, Brzóska MM. Review of polyphenol-rich products as potential protective and therapeutic factors against cadmium hepatotoxicity. J Appl Toxicol 2019;39:117-45. [PMID: 30216481 DOI: 10.1002/jat.3709] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
69 Targher G, Bertolini L, Chonchol M, Rodella S, Zoppini G, Lippi G, Zenari L, Bonora E. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients. Diabetologia. 2010;53:1341-1348. [PMID: 20369224 DOI: 10.1007/s00125-010-1720-1] [Cited by in Crossref: 94] [Cited by in F6Publishing: 87] [Article Influence: 7.8] [Reference Citation Analysis]
70 Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA, Cardoso CR. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int. 2009;29:113-119. [PMID: 18384521 DOI: 10.1111/j.1478-3231.2008.01718.x] [Cited by in Crossref: 304] [Cited by in F6Publishing: 287] [Article Influence: 21.7] [Reference Citation Analysis]
71 Zhan YT, Zhang C, Li L, Bi CS, Song X, Zhang ST. Non-alcoholic fatty liver disease is not related to the incidence of diabetic nephropathy in Type 2 Diabetes. Int J Mol Sci 2012;13:14698-706. [PMID: 23203089 DOI: 10.3390/ijms131114698] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
72 Lambert JE, Parnell JA, Eksteen B, Raman M, Bomhof MR, Rioux KP, Madsen KL, Reimer RA. Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol. BMC Gastroenterol 2015;15:169. [PMID: 26635079 DOI: 10.1186/s12876-015-0400-5] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 5.6] [Reference Citation Analysis]
73 Yang JS, Kim JY, Lee JC, Moon MH. Investigation of lipidomic perturbations in oxidatively stressed subcellular organelles and exosomes by asymmetrical flow field–flow fractionation and nanoflow ultrahigh performance liquid chromatography–tandem mass spectrometry. Analytica Chimica Acta 2019;1073:79-89. [DOI: 10.1016/j.aca.2019.04.069] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
74 Zhan YT, An W. Roles of liver innate immune cells in nonalcoholic fatty liver disease. World J Gastroenterol 2010; 16(37): 4652-4660 [PMID: 20872965 DOI: 10.3748/wjg.v16.i37.4652] [Cited by in CrossRef: 59] [Cited by in F6Publishing: 62] [Article Influence: 4.9] [Reference Citation Analysis]
75 Zang S, Chen J, Song Y, Bai L, Chen J, Chi X, He F, Sheng H, Wang J, Xie S, Xie W, Yang Y, Zhang J, Zheng M, Zou Z, Wang B, Shi J; Chinese NAFLD Clinical Research Network (CNAFLD CRN). Haptoglobin Genotype and Vitamin E Versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis in China: A Multicenter, Randomized, Placebo-Controlled Trial Design. Adv Ther 2018;35:218-31. [PMID: 29411270 DOI: 10.1007/s12325-018-0670-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
76 Bellinato F, Goio I, Malara G, Rosato A, Targher G, Girolomoni G, Gisondi P. Non-Alcoholic Fatty Liver Disease Is Associated With Reduced Glomerular Filtration Rate in Patients With Chronic Plaque Psoriasis. J Cutan Med Surg 2021;:12034754211066906. [PMID: 34894782 DOI: 10.1177/12034754211066906] [Reference Citation Analysis]
77 Afarideh M, Aryan Z, Ghajar A, Ganji M, Ghaemi F, Saadat M, Heidari B, Mechanick JI, Esteghamati A. Association of non-alcoholic fatty liver disease with microvascular complications of type 2 diabetes. Prim Care Diabetes 2019;13:505-14. [PMID: 31054837 DOI: 10.1016/j.pcd.2019.03.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
78 Wang W, Wang C, Ding XQ, Pan Y, Gu TT, Wang MX, Liu YL, Wang FM, Wang SJ, Kong LD. Quercetin and allopurinol reduce liver thioredoxin-interacting protein to alleviate inflammation and lipid accumulation in diabetic rats. Br J Pharmacol 2013;169:1352-71. [PMID: 23647015 DOI: 10.1111/bph.12226] [Cited by in Crossref: 103] [Cited by in F6Publishing: 95] [Article Influence: 12.9] [Reference Citation Analysis]
79 Kim BY, Jung CH, Mok JO, Kang SK, Kim CH. Prevalences of diabetic retinopathy and nephropathy are lower in Korean type 2 diabetic patients with non-alcoholic fatty liver disease. J Diabetes Investig 2014;5:170-5. [PMID: 24843757 DOI: 10.1111/jdi.12139] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
80 Hashimoto Y, Hamaguchi M, Kaji A, Sakai R, Kitagawa N, Fukui M. Serum levels of mac-2 binding protein are associated with diabetic microangiopathy and macroangiopathy in people with type 2 diabetes. BMJ Open Diabetes Res Care 2020;8:e001189. [PMID: 32847841 DOI: 10.1136/bmjdrc-2020-001189] [Reference Citation Analysis]
81 Goldberg RB, Tripputi MT, Boyko EJ, Budoff M, Chen ZZ, Clark JM, Dabelea DM, Edelstein SL, Gerszten RE, Horton E, Mather KJ, Perreault L, Temprosa M, Wallia A, Watson K, Irfan Z. Hepatic Fat in Participants With and Without Incident Diabetes in the Diabetes Prevention Program Outcome Study. J Clin Endocrinol Metab 2021;106:e4746-65. [PMID: 33705543 DOI: 10.1210/clinem/dgab160] [Reference Citation Analysis]
82 Forlani G, Giorda C, Manti R, Mazzella N, De Cosmo S, Rossi MC, Nicolucci A, Di Bartolo P, Ceriello A, Guida P; AMD-Annals Study Group. The Burden of NAFLD and Its Characteristics in a Nationwide Population with Type 2 Diabetes. J Diabetes Res 2016;2016:2931985. [PMID: 27123461 DOI: 10.1155/2016/2931985] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
83 Alzahrani SH, Baig M, Bashawri JI, Aashi MM, Shaibi FK, Alqarni DA. Prevalence and Association of Elevated Liver Transaminases in Type 2 Diabetes Mellitus Patients in Jeddah, Saudi Arabia. Cureus 2019;11:e5166. [PMID: 31528516 DOI: 10.7759/cureus.5166] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
84 Armstrong MJ, Adams LA, Canbay A, Syn WK. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology. 2014;59:1174-1197. [PMID: 24002776 DOI: 10.1002/hep.26717] [Cited by in Crossref: 301] [Cited by in F6Publishing: 281] [Article Influence: 37.6] [Reference Citation Analysis]
85 Grecian SM, McLachlan S, Fallowfield JA, Kearns PKA, Hayes PC, Guha NI, Morling JR, Glancy S, Williamson RM, Reynolds RM, Frier BM, Zammitt NN, Price JF, Strachan MWJ. Non-invasive risk scores do not reliably identify future cirrhosis or hepatocellular carcinoma in Type 2 diabetes: The Edinburgh type 2 diabetes study.Liver Int. 2020;40:2252-2262. [PMID: 32638496 DOI: 10.1111/liv.14590] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
86 Zhang Z, Wang J, Wang H. Correlation of blood glucose, serum chemerin and insulin resistance with NAFLD in patients with type 2 diabetes mellitus. Exp Ther Med 2018;15:2936-40. [PMID: 29456698 DOI: 10.3892/etm.2018.5753] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
87 Lee YH, Cho Y, Lee BW, Park CY, Lee DH, Cha BS, Rhee EJ. Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis. Diabetes Metab J. 2019;43:31-45. [PMID: 30793550 DOI: 10.4093/dmj.2019.0011] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 20.0] [Reference Citation Analysis]
88 Caballeria L, Augustin S, Broquetas T, Morillas RM, Vergara M, Virolés S, Hernández MR, Serra I, Goday A, Vila L, Siso-Almirall A, Solans R, Fernández-Real JM, Carrión JA, Graupera I, Ginès P. Recommendations for the detection, diagnosis and follow-up of patients with non-alcoholic fatty liver disease in primary and hospital care. Med Clin (Barc) 2019;153:169-77. [PMID: 31178295 DOI: 10.1016/j.medcli.2019.01.030] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
89 Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66:1138-1153. [PMID: 28314735 DOI: 10.1136/gutjnl-2017-313884] [Cited by in Crossref: 384] [Cited by in F6Publishing: 366] [Article Influence: 76.8] [Reference Citation Analysis]
90 Fruci B, Giuliano S, Mazza A, Malaguarnera R, Belfiore A. Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment. Int J Mol Sci. 2013;14:22933-22966. [PMID: 24264040 DOI: 10.3390/ijms141122933] [Cited by in Crossref: 62] [Cited by in F6Publishing: 62] [Article Influence: 6.9] [Reference Citation Analysis]
91 Targher G, Bertolini L, Rodella S, Lippi G, Zoppini G, Chonchol M. Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clin J Am Soc Nephrol 2010;5:2166-71. [PMID: 20724519 DOI: 10.2215/CJN.05050610] [Cited by in Crossref: 128] [Cited by in F6Publishing: 53] [Article Influence: 10.7] [Reference Citation Analysis]
92 Pallayova M, Taheri S. Non-alcoholic fatty liver disease in obese adults: clinical aspects and current management strategies. Clin Obes. 2014;4:243-253. [PMID: 25825857 DOI: 10.1111/cob.12068] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
93 Barchetta I, Del Ben M, Angelico F, Di Martino M, Fraioli A, La Torre G, Saulle R, Perri L, Morini S, Tiberti C, Bertoccini L, Cimini FA, Panimolle F, Catalano C, Baroni MG, Cavallo MG. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial. BMC Med. 2016;14:92. [PMID: 27353492 DOI: 10.1186/s12916-016-0638-y] [Cited by in Crossref: 76] [Cited by in F6Publishing: 70] [Article Influence: 12.7] [Reference Citation Analysis]
94 Tang W, Xu Q, Hong T, Tong G, Feng W, Shen S, Bi Y, Zhu D. Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies. Diabetes Metab Res Rev. 2016;32:200-216. [PMID: 26381272 DOI: 10.1002/dmrr.2713] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]
95 Zhao M, Hu Y, Shi C, Wang K, Li J, Song J, Huo C, Xi Y, Bu S, Huang Q. NFI, a clinical scoring tool for predicting non-alcoholic fatty liver in the Chinese population. Public Health 2021;202:12-7. [PMID: 34875531 DOI: 10.1016/j.puhe.2021.10.012] [Reference Citation Analysis]
96 Ahmed MH, Barakat S, Almobarak AO. Nonalcoholic fatty liver disease and cardiovascular disease: has the time come for cardiologists to be hepatologists? J Obes. 2012;2012:483135. [PMID: 23320150 DOI: 10.1155/2012/483135] [Cited by in Crossref: 46] [Cited by in F6Publishing: 52] [Article Influence: 4.6] [Reference Citation Analysis]
97 Katsiki N, Anagnostis P, Kotsa K, Goulis DG, Mikhailidis DP. Obesity, Metabolic Syndrome and the Risk of Microvascular Complications in Patients with Diabetes mellitus. Curr Pharm Des. 2019;25:2051-2059. [PMID: 31298151 DOI: 10.2174/1381612825666190708192134] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
98 Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10:330-344. [PMID: 23507799 DOI: 10.1038/nrgastro.2013.41] [Cited by in Crossref: 861] [Cited by in F6Publishing: 806] [Article Influence: 95.7] [Reference Citation Analysis]
99 Zhou YJ, Zhou YF, Zheng JN, Liu WY, Van Poucke S, Zou TT, Zhang DC, Shen S, Shi KQ, Wang XD, Zheng MH. NAFL screening score: A basic score identifying ultrasound-diagnosed non-alcoholic fatty liver. Clin Chim Acta. 2017;475:44-50. [PMID: 28964832 DOI: 10.1016/j.cca.2017.09.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
100 Bonora E, Targher G. Increased risk of cardiovascular disease and chronic kidney disease in NAFLD. Nat Rev Gastroenterol Hepatol. 2012;9:372-381. [PMID: 22565095 DOI: 10.1038/nrgastro.2012.79] [Cited by in Crossref: 77] [Cited by in F6Publishing: 71] [Article Influence: 7.7] [Reference Citation Analysis]
101 Houlihan DD, Armstrong MJ, Davidov Y, Hodson J, Nightingale P, Rowe IA, Paris S, Gunson BK, Bramhall SB, Mutimer DJ, Neuberger JM, Newsome PN. Renal function in patients undergoing transplantation for nonalcoholic steatohepatitis cirrhosis: time to reconsider immunosuppression regimens? Liver Transpl. 2011;17:1292-1298. [PMID: 21761549 DOI: 10.1002/lt.22382] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 5.0] [Reference Citation Analysis]
102 Eslam M, Ahmed A, Després JP, Jha V, Halford JCG, Wei Chieh JT, Harris DCH, Nangaku M, Colagiuri S, Targher G, Joshi S, Byrne CD, Khunti K, Nguyen MH, Gish RG, George J. Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases. Lancet Gastroenterol Hepatol 2021;6:743-53. [PMID: 34265276 DOI: 10.1016/S2468-1253(21)00132-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
103 Ahmed MH, Byrne CD. Non-Alcoholic Fatty Liver Disease. In: Byrne CD, Wild SH, editors. The Metabolic Syndrome. Oxford: Wiley-Blackwell; 2011. pp. 245-77. [DOI: 10.1002/9781444347319.ch15] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
104 Caussy C. Should We Screen High-Risk Populations for NAFLD? Curr Hepatology Rep 2019;18:433-43. [DOI: 10.1007/s11901-019-00497-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
105 Cortés-rojo C, Montoya-pérez R, Rodríguez-orozco AR, Saavedra-molina A, Calderón-cortés E. Avocado Oil and Diabetic Complications Related to Mitochondrial Dysfunction. Bioactive Food as Dietary Interventions for Diabetes. Elsevier; 2019. pp. 89-101. [DOI: 10.1016/b978-0-12-813822-9.00006-0] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
106 Choi JM, Chung GE, Kang SJ, Kwak MS, Yang JI, Park B, Yim JY. Association Between Anxiety and Depression and Nonalcoholic Fatty Liver Disease. Front Med (Lausanne) 2020;7:585618. [PMID: 33537324 DOI: 10.3389/fmed.2020.585618] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
107 Adiga US, Malawadi BN. Association of Diabetic Nephropathy and Liver Disorders. J Clin Diagn Res 2016;10:BC05-7. [PMID: 27891331 DOI: 10.7860/JCDR/2016/21672.8728] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
108 Wong F. Renal diseases and the liver. Clin Liver Dis 2011;15:39-53. [PMID: 21111992 DOI: 10.1016/j.cld.2010.09.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
109 Grecian SM, McLachlan S, Fallowfield JA, Hayes PC, Guha IN, Morling JR, Glancy S, Williamson RM, Reynolds RM, Frier BM, Zammitt NN, Price JF, Strachan MWJ. Addition of hyaluronic acid to the FIB-4 liver fibrosis score improves prediction of incident cirrhosis and hepatocellular carcinoma in type 2 diabetes: The Edinburgh Type 2 Diabetes Study. Obes Sci Pract 2021;7:497-508. [PMID: 34631129 DOI: 10.1002/osp4.484] [Reference Citation Analysis]
110 Hsieh MH, Wu KT, Chen YY, Yang JF, Lin WY, Chang NC, Lin CY, Huang CK, Wang CL, Chuang HY, Lin SC, Hsu YK, Tsai YS, Chuang WL, Yu ML, Dai CY. Higher NAFLD fibrosis score is associated with impaired eGFR. J Formos Med Assoc. 2020;119:496-503. [PMID: 31353118 DOI: 10.1016/j.jfma.2019.07.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
111 Corrao S, Natoli G, Argano C. Nonalcoholic fatty liver disease is associated with intrahepatic cholangiocarcinoma and not with extrahepatic form: definitive evidence from meta-analysis and trial sequential analysis. Eur J Gastroenterol Hepatol 2021;33:62-8. [PMID: 32091438 DOI: 10.1097/MEG.0000000000001684] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
112 Su X, Xu J, Zheng C. The relationship between non-alcoholic fatty liver and skeletal muscle mass to visceral fat area ratio in women with type 2 diabetes. BMC Endocr Disord 2019;19:76. [PMID: 31315613 DOI: 10.1186/s12902-019-0404-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
113 Targher G, Byrne CD. Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease. Nat Rev Nephrol. 2017;13:297-310. [PMID: 28218263 DOI: 10.1038/nrneph.2017.16] [Cited by in Crossref: 115] [Cited by in F6Publishing: 110] [Article Influence: 23.0] [Reference Citation Analysis]
114 Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010;53:372-384. [PMID: 20494470 DOI: 10.1016/j.jhep.2010.04.008] [Cited by in Crossref: 637] [Cited by in F6Publishing: 605] [Article Influence: 53.1] [Reference Citation Analysis]
115 Marshall SM, Flyvbjerg A. Diabetic Nephropathy. In: Holt RIG, Cockram CS, Flyvbjerg A, Goldstein BJ, editors. Textbook of Diabetes. Oxford: Wiley-Blackwell; 2010. pp. 599-614. [DOI: 10.1002/9781444324808.ch37] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
116 Song D, Li C, Wang Z, Zhao Y, Shen B, Zhao W. Association of non-alcoholic fatty liver disease with diabetic retinopathy in type 2 diabetic patients: A meta-analysis of observational studies. J Diabetes Investig 2021;12:1471-9. [PMID: 33372390 DOI: 10.1111/jdi.13489] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
117 Targher G, Chonchol M, Zoppini G, Abaterusso C, Bonora E. Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: Is there a link? Journal of Hepatology 2011;54:1020-9. [DOI: 10.1016/j.jhep.2010.11.007] [Cited by in Crossref: 101] [Cited by in F6Publishing: 99] [Article Influence: 9.2] [Reference Citation Analysis]
118 Choe AR, Ryu DR, Kim HY, Lee HA, Lim J, Kim JS, Lee JK, Kim TH, Yoo K. Noninvasive indices for predicting nonalcoholic fatty liver disease in patients with chronic kidney disease. BMC Nephrol 2020;21:50. [PMID: 32066395 DOI: 10.1186/s12882-020-01718-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
119 Bulum T, Kolarić B, Duvnjak M, Duvnjak L. Alkaline phosphatase is independently associated with renal function in normoalbuminuric type 1 diabetic patients. Ren Fail 2014;36:372-7. [PMID: 24455970 DOI: 10.3109/0886022X.2013.872569] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
120 Hydes TJ, Summers N, Brown E, Alam U, Thomaides-Brears H, Wilding JPH, Cuthbertson DJ. Mechanisms, screening modalities and treatment options for individuals with non-alcoholic fatty liver disease and type 2 diabetes. Diabet Med 2020;37:1793-806. [PMID: 32619031 DOI: 10.1111/dme.14356] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
121 Dai W, Ye L, Liu A, Wen SW, Deng J, Wu X, Lai Z. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: A meta-analysis. Medicine (Baltimore). 2017;96:e8179. [PMID: 28953675 DOI: 10.1097/md.0000000000008179] [Cited by in Crossref: 101] [Cited by in F6Publishing: 51] [Article Influence: 20.2] [Reference Citation Analysis]
122 Kubota M, Watanabe R, Yamaguchi M, Hosojima M, Saito A, Fujii M, Fujimura S, Kadowaki M. Rice endosperm protein slows progression of fatty liver and diabetic nephropathy in Zucker diabetic fatty rats. Br J Nutr 2016;116:1326-35. [PMID: 27724997 DOI: 10.1017/S0007114516003512] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 2.2] [Reference Citation Analysis]
123 Lombardi R, Airaghi L, Targher G, Serviddio G, Maffi G, Mantovani A, Maffeis C, Colecchia A, Villani R, Rinaldi L, Orsi E, Pisano G, Adinolfi LE, Fargion S, Fracanzani AL. Liver fibrosis by FibroScan® independently of established cardiovascular risk parameters associates with macrovascular and microvascular complications in patients with type 2 diabetes. Liver Int 2020;40:347-54. [PMID: 31612634 DOI: 10.1111/liv.14274] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
124 An JN, Joo SK, Koo BK, Kim JH, Oh S, Kim W. Portal inflammation predicts renal dysfunction in patients with nonalcoholic fatty liver disease. Hepatol Int 2020;14:798-807. [DOI: 10.1007/s12072-020-10063-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
125 Hosokawa K, Takata T, Sugihara T, Matono T, Koda M, Kanda T, Taniguchi S, Ida A, Mae Y, Yamamoto M, Iyama T, Fukuda S, Isomoto H. Ipragliflozin Ameliorates Endoplasmic Reticulum Stress and Apoptosis through Preventing Ectopic Lipid Deposition in Renal Tubules. Int J Mol Sci 2019;21:E190. [PMID: 31888083 DOI: 10.3390/ijms21010190] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
126 Zhang M, Hu ML, Huang JJ, Xia SS, Yang Y, Dong K. Association of leukocyte telomere length with non-alcoholic fatty liver disease in patients with type 2 diabetes. Chin Med J (Engl) 2019;132:2927-33. [PMID: 31809318 DOI: 10.1097/CM9.0000000000000559] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
127 Targher G, Kendrick J, Smits G, Chonchol M. Relationship between serum gamma-glutamyltransferase and chronic kidney disease in the United States adult population. Findings from the National Health and Nutrition Examination Survey 2001-2006. Nutr Metab Cardiovasc Dis. 2010;20:583-590. [PMID: 19699624 DOI: 10.1016/j.numecd.2009.05.012] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 3.1] [Reference Citation Analysis]
128 Athyros VG, Tziomalos K, Katsiki N, Doumas M, Karagiannis A, Mikhailidis DP. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. World J Gastroenterol 2015; 21(22): 6820-6834 [PMID: 26078558 DOI: 10.3748/wjg.v21.i22.6820] [Cited by in CrossRef: 88] [Cited by in F6Publishing: 80] [Article Influence: 12.6] [Reference Citation Analysis]
129 Ferreira VS, Pernambuco RB, Lopes EP, Morais CN, Rodrigues MC, Arruda MJ, Silva LM, Vilar L. Frequency and risk factors associated with non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. Arq Bras Endocrinol Metabol. 2010;54:362-368. [PMID: 20625647 DOI: 10.1590/s0004-27302010000400004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
130 Ahmed MH, Abu EO, Byrne CD. Non-Alcoholic Fatty Liver Disease (NAFLD): new challenge for general practitioners and important burden for health authorities? Prim Care Diabetes. 2010;4:129-137. [PMID: 20299294 DOI: 10.1016/j.pcd.2010.02.004] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 3.3] [Reference Citation Analysis]
131 Liu HW, Liu JS, Kuo KL. Association of nonalcoholic fatty liver and chronic kidney disease: An analysis of 37,825 cases from health checkup center in Taiwan. Ci Ji Yi Xue Za Zhi 2020;32:65-9. [PMID: 32110523 DOI: 10.4103/tcmj.tcmj_233_18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
132 Targher G, Chonchol MB, Byrne CD. CKD and nonalcoholic fatty liver disease. Am J Kidney Dis. 2014;64:638-652. [PMID: 25085644 DOI: 10.1053/j.ajkd.2014.05.019] [Cited by in Crossref: 104] [Cited by in F6Publishing: 96] [Article Influence: 13.0] [Reference Citation Analysis]
133 Kromrey ML, Ittermann T, Berning M, Kolb C, Hoffmann RT, Lerch MM, Völzke H, Kühn JP. Accuracy of ultrasonography in the assessment of liver fat compared with MRI. Clin Radiol 2019;74:539-46. [PMID: 30955836 DOI: 10.1016/j.crad.2019.02.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
134 Lin TY, Chen YJ, Chen WL, Peng TC. The Relationship between Nonalcoholic Fatty Liver Disease and Retinopathy in NHANES III. PLoS One. 2016;11:e0165970. [PMID: 27802330 DOI: 10.1371/journal.pone.0165970] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
135 Fante RJ, Gardner TW, Sundstrom JM. Current and future management of diabetic retinopathy: a personalized evidence-based approach. Diabetes Manag (Lond) 2013;3:481-94. [PMID: 24932222 DOI: 10.2217/dmt.13.50] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
136 Basterra-Gortari FJ, Martínez-González MA. Mediterranean diet in type 2 diabetes. Diabetologia 2008;51:1933-4; author reply 1935. [PMID: 18712346 DOI: 10.1007/s00125-008-1121-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
137 Ota T. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH). Adv Exp Med Biol 2021;1261:223-9. [PMID: 33783745 DOI: 10.1007/978-981-15-7360-6_20] [Reference Citation Analysis]
138 Ye JH, Chao J, Chang ML, Peng WH, Cheng HY, Liao JW, Pao LH. Pentoxifylline ameliorates non-alcoholic fatty liver disease in hyperglycaemic and dyslipidaemic mice by upregulating fatty acid β-oxidation. Sci Rep 2016;6:33102. [PMID: 27612024 DOI: 10.1038/srep33102] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
139 Machado MV, Gonçalves S, Carepa F, Coutinho J, Costa A, Cortez-pinto H. Impaired renal function in morbid obese patients with nonalcoholic fatty liver disease. Liver Int 2012;32:241-8. [DOI: 10.1111/j.1478-3231.2011.02623.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 4.4] [Reference Citation Analysis]
140 Khneizer G, Rizvi S, Gawrieh S. Non-alcoholic Fatty Liver Disease and Diabetes Mellitus. Adv Exp Med Biol 2021;1307:417-40. [PMID: 32424494 DOI: 10.1007/5584_2020_532] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
141 Orlić L, Mikolasevic I, Bagic Z, Racki S, Stimac D, Milic S. Chronic kidney disease and nonalcoholic Fatty liver disease-is there a link? Gastroenterol Res Pract 2014;2014:847539. [PMID: 24729784 DOI: 10.1155/2014/847539] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 3.8] [Reference Citation Analysis]
142 Wijarnpreecha K, Aby ES, Ahmed A, Kim D. Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease. Clin Mol Hepatol 2021;27:221-35. [PMID: 33317243 DOI: 10.3350/cmh.2020.0239] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
143 Gupta J, Gaikwad AB, Tikoo K. Hepatic expression profiling shows involvement of PKC epsilon, DGK eta, Tnfaip, and Rho kinase in type 2 diabetic nephropathy rats. J Cell Biochem 2010;111:944-54. [DOI: 10.1002/jcb.22783] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
144 Lin L, Lu J, Huang X, Ding L, Huang Y, Wang P, Peng K, Zhang D, Xu Y, Xu M, Chen Y, Bi Y, Wang W, Xu Y. Nonalcoholic fatty liver disease is associated with low-grade albuminuria in Chinese adults (change not displayed). QJM 2016;109:737-43. [DOI: 10.1093/qjmed/hcw070] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
145 Wang X, Zhao X, Gu Y, Zhu X, Yin T, Tang Z, Yuan J, Chen W, OuYang R, Yao L, Zhang R, Yuan J, Zhou R, Sun Y, Cui S. Effects of Exenatide and Humalog Mix25 on Fat Distribution, Insulin Sensitivity, and β-Cell Function in Normal BMI Patients with Type 2 Diabetes and Visceral Adiposity. J Diabetes Res 2020;2020:9783859. [PMID: 32566685 DOI: 10.1155/2020/9783859] [Reference Citation Analysis]
146 Brea A, Puzo J. Non-alcoholic fatty liver disease and cardiovascular risk. Int J Cardiol. 2013;167:1109-1117. [PMID: 23141876 DOI: 10.1016/j.ijcard.2012.09.085] [Cited by in Crossref: 55] [Cited by in F6Publishing: 46] [Article Influence: 5.5] [Reference Citation Analysis]
147 Butt AA, Wang X, Fried LF. HCV infection and the incidence of CKD. Am J Kidney Dis. 2011;57:396-402. [PMID: 21185632 DOI: 10.1053/j.ajkd.2010.09.023] [Cited by in Crossref: 82] [Cited by in F6Publishing: 73] [Article Influence: 6.8] [Reference Citation Analysis]
148 Lai YC, Cheng BC, Hwang JC, Lee YT, Chiu CH, Kuo LC, Chen JB. Association of fatty liver disease with nonfatal cardiovascular events in patients undergoing maintenance hemodialysis. Nephron Clin Pract. 2013;124:218-223. [PMID: 24503573 DOI: 10.1159/000357952] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
149 Nunez DJ, Alexander M, Yerges-Armstrong L, Singh G, Byttebier G, Fabbrini E, Waterworth D, Meininger G, Galwey N, Wallentin L, White HD, Vannieuwenhuyse B, Alazawi W, Kendrick S, Sattar N, Ferrannini E. Factors influencing longitudinal changes of circulating liver enzyme concentrations in subjects randomized to placebo in four clinical trials. Am J Physiol Gastrointest Liver Physiol 2019;316:G372-86. [PMID: 30495974 DOI: 10.1152/ajpgi.00051.2018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
150 Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62:S47-S64. [PMID: 25920090 DOI: 10.1016/j.jhep.2014.12.012] [Cited by in Crossref: 1011] [Cited by in F6Publishing: 958] [Article Influence: 168.5] [Reference Citation Analysis]
151 Lee CH, Seto WK, Ieong K, Lui DTW, Fong CHY, Wan HY, Chow WS, Woo YC, Yuen MF, Lam KSL. Development of a Non-Invasive Liver Fibrosis Score Based on Transient Elastography for Risk Stratification in Patients with Type 2 Diabetes. Endocrinol Metab (Seoul) 2021;36:134-45. [PMID: 33677935 DOI: 10.3803/EnM.2020.887] [Reference Citation Analysis]
152 Heidari Z, Gharebaghi A. Prevalence of Non Alcoholic Fatty Liver Disease and its Association with Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus. J Clin Diagn Res 2017;11:OC04-7. [PMID: 28658824 DOI: 10.7860/JCDR/2017/25931.9823] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
153 Hazlehurst JM, Tomlinson JW. Non-alcoholic fatty liver disease in common endocrine disorders. Eur J Endocrinol 2013;169:R27-37. [PMID: 23653455 DOI: 10.1530/EJE-13-0296] [Cited by in Crossref: 51] [Cited by in F6Publishing: 22] [Article Influence: 5.7] [Reference Citation Analysis]
154 Hazlehurst JM, Woods C, Marjot T, Cobbold JF, Tomlinson JW. Non-alcoholic fatty liver disease and diabetes. Metabolism 2016;65:1096-108. [PMID: 26856933 DOI: 10.1016/j.metabol.2016.01.001] [Cited by in Crossref: 205] [Cited by in F6Publishing: 195] [Article Influence: 34.2] [Reference Citation Analysis]
155 Cernea S, Raz I. NAFLD in type 2 diabetes mellitus: Still many challenging questions. Diabetes Metab Res Rev 2021;37. [DOI: 10.1002/dmrr.3386] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
156 Rosato V, Masarone M, Dallio M, Federico A, Aglitti A, Persico M. NAFLD and Extra-Hepatic Comorbidities: Current Evidence on a Multi-Organ Metabolic Syndrome. Int J Environ Res Public Health 2019;16:E3415. [PMID: 31540048 DOI: 10.3390/ijerph16183415] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 7.7] [Reference Citation Analysis]
157 Musso G, Gambino R, Tabibian JH, Ekstedt M, Kechagias S, Hamaguchi M, Hultcrantz R, Hagström H, Yoon SK, Charatcharoenwitthaya P, George J, Barrera F, Hafliðadóttir S, Björnsson ES, Armstrong MJ, Hopkins LJ, Gao X, Francque S, Verrijken A, Yilmaz Y, Lindor KD, Charlton M, Haring R, Lerch MM, Rettig R, Völzke H, Ryu S, Li G, Wong LL, Machado M, Cortez-Pinto H, Yasui K, Cassader M. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med 2014;11:e1001680. [PMID: 25050550 DOI: 10.1371/journal.pmed.1001680] [Cited by in Crossref: 283] [Cited by in F6Publishing: 269] [Article Influence: 35.4] [Reference Citation Analysis]
158 Zhang M, Li L, Chen J, Li B, Zhan Y, Zhang C. Presence of diabetic retinopathy is lower in type 2 diabetic patients with non-alcoholic fatty liver disease. Medicine (Baltimore) 2019;98:e15362. [PMID: 31045779 DOI: 10.1097/MD.0000000000015362] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
159 Rhee EJ. Nonalcoholic Fatty Liver Disease and Diabetes: An Epidemiological Perspective. Endocrinol Metab (Seoul) 2019;34:226-33. [PMID: 31565874 DOI: 10.3803/EnM.2019.34.3.226] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 12.0] [Reference Citation Analysis]
160 Sirota JC, McFann K, Targher G, Chonchol M, Jalal DI. Association between nonalcoholic liver disease and chronic kidney disease: an ultrasound analysis from NHANES 1988-1994. Am J Nephrol. 2012;36:466-471. [PMID: 23128368 DOI: 10.1159/000343885] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 4.6] [Reference Citation Analysis]
161 Di Sessa A, Guarino S, Passaro AP, Liguori L, Umano GR, Cirillo G, Miraglia Del Giudice E, Marzuillo P. NAFLD and renal function in children: is there a genetic link?Expert Rev Gastroenterol Hepatol. 2021;1-10. [PMID: 33851883 DOI: 10.1080/17474124.2021.1906649] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
162 Huh JH, Kim JY, Choi E, Kim JS, Chang Y, Sung KC. The fatty liver index as a predictor of incident chronic kidney disease in a 10-year prospective cohort study. PLoS One. 2017;12:e0180951. [PMID: 28738057 DOI: 10.1371/journal.pone.0180951] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
163 Behairy MA, Sherief AF, Hussein HA. Prevalence of non-alcoholic fatty liver disease among patients with non-diabetic chronic kidney disease detected by transient elastography. Int Urol Nephrol 2021. [PMID: 33675475 DOI: 10.1007/s11255-021-02815-9] [Reference Citation Analysis]
164 de Alwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol. 2008;48 Suppl 1:S104-S112. [PMID: 18304679 DOI: 10.1016/j.jhep.2008.01.009] [Cited by in Crossref: 358] [Cited by in F6Publishing: 349] [Article Influence: 25.6] [Reference Citation Analysis]
165 Wang Y, Yu Y, Wan H, Chen Y, Xia F, Zhang W, Zhang K, Gu X, Zhang Y, Lin Z, Yu Y, Wang N, Lu Y. Lower eGFR is associated with increased probability of liver fibrosis in Chinese diabetic patients. Diabetes Metab Res Rev 2020;36:e3294. [PMID: 32017389 DOI: 10.1002/dmrr.3294] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
166 Xu X, Lu L, Dong Q, Li X, Zhang N, Xin Y, Xuan S. Research advances in the relationship between nonalcoholic fatty liver disease and atherosclerosis. Lipids Health Dis. 2015;14:158. [PMID: 26631018 DOI: 10.1186/s12944-015-0141-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
167 Targher G, Chonchol M, Pichiri I, Zoppini G. Risk of cardiovascular disease and chronic kidney disease in diabetic patients with non-alcoholic fatty liver disease: just a coincidence? J Endocrinol Invest 2011;34:544-51. [PMID: 21427524 DOI: 10.3275/7614] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
168 Perdomo CM, Garcia-Fernandez N, Escalada J. Diabetic Kidney Disease, Cardiovascular Disease and Non-Alcoholic Fatty Liver Disease: A New Triumvirate? J Clin Med 2021;10:2040. [PMID: 34068699 DOI: 10.3390/jcm10092040] [Reference Citation Analysis]
169 Lecube A, Hernández C, Simó R. Glucose abnormalities in non-alcoholic fatty liver disease and chronic hepatitis C virus infection: the role of iron overload. Diabetes Metab Res Rev 2009;25:403-10. [PMID: 19444865 DOI: 10.1002/dmrr.972] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
170 Chen Z, Qin H, Qiu S, Chen G, Chen Y. Correlation of triglyceride to high-density lipoprotein cholesterol ratio with nonalcoholic fatty liver disease among the non-obese Chinese population with normal blood lipid levels: a retrospective cohort research. Lipids Health Dis 2019;18:162. [PMID: 31399032 DOI: 10.1186/s12944-019-1104-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
171 Szczuko M, Kaczkan M, Małgorzewicz S, Rutkowski P, Dębska-Ślizień A, Stachowska E. The C18:3n6/C22:4n6 ratio is a good lipid marker of chronic kidney disease (CKD) progression. Lipids Health Dis 2020;19:77. [PMID: 32303226 DOI: 10.1186/s12944-020-01258-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
172 Greco C, Nascimbeni F, Carubbi F, Andreone P, Simoni M, Santi D. Association of Nonalcoholic Fatty Liver Disease (NAFLD) with Peripheral Diabetic Polyneuropathy: A Systematic Review and Meta-Analysis. J Clin Med 2021;10:4466. [PMID: 34640482 DOI: 10.3390/jcm10194466] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
173 Targher G, Pichiri I, Zoppini G, Trombetta M, Bonora E. Increased prevalence of chronic kidney disease in patients with Type 1 diabetes and non-alcoholic fatty liver. Diabet Med. 2012;29:220-226. [PMID: 21883436 DOI: 10.1111/j.1464-5491.2011.03427.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 4.3] [Reference Citation Analysis]
174 Kiapidou S, Liava C, Kalogirou M, Akriviadis E, Sinakos E. Chronic kidney disease in patients with non-alcoholic fatty liver disease: What the Hepatologist should know? Ann Hepatol 2020;19:134-44. [PMID: 31606352 DOI: 10.1016/j.aohep.2019.07.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
175 Hamed AE, Elsahar M, Elwan NM, El-Nakeep S, Naguib M, Soliman HH, Aboubakr AA, AbdelMaqsod A, Sedrak H, Assaad SN, Elwakil R, Esmat G, Salh S, Mostafa T, Mogawer S, Sadek SE, Saber MM, Ezelarab H, Mahmoud AA, Sultan S, El Kassas M, Kamal E, ElSayed NM, Moussa S; Jury, Reviewers and Advisory Board: Sherif Abdelfattah, Samir Helmy ASSAAD-KHALIL, Ahmed Ali Elgarem, Rawia Khater, Amr Helmi, Hisham Elborlsy, Abdelhamid Attia (President of the Arab Federation Of Evidence-Based Medicine). Managing diabetes and liver disease association: Practice guidelines from the Egyptian Association for the Study of Liver and Gastrointestinal Disease (EASLGD). Arab J Gastroenterol. 2019;20:61-63. [PMID: 30852101 DOI: 10.1016/j.ajg.2019.02.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
176 Heda R, Yazawa M, Shi M, Bhaskaran M, Aloor FZ, Thuluvath PJ, Satapathy SK. Non-alcoholic fatty liver and chronic kidney disease: Retrospect, introspect, and prospect. World J Gastroenterol 2021; 27(17): 1864-1882 [PMID: 34007127 DOI: 10.3748/wjg.v27.i17.1864] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
177 Padda J, Khalid K, Khedr A, Tasnim F, Al-Ewaidat OA, Cooper AC, Jean-Charles G. Non-Alcoholic Fatty Liver Disease and Its Association With Diabetes Mellitus. Cureus 2021;13:e17321. [PMID: 34557367 DOI: 10.7759/cureus.17321] [Reference Citation Analysis]
178 Kim J, Lee M, Kim SY, Kim JH, Nam JS, Chun SW, Park SE, Kim KJ, Lee YH, Nam JY, Kang ES. Non-Laboratory-Based Simple Screening Model for Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Developed Using Multi-Center Cohorts. Endocrinol Metab (Seoul) 2021;36:823-34. [PMID: 34474517 DOI: 10.3803/EnM.2021.1074] [Reference Citation Analysis]
179 Marjot T, Sbardella E, Moolla A, Hazlehurst JM, Tan GD, Ainsworth M, Cobbold JFL, Tomlinson JW. Prevalence and severity of non-alcoholic fatty liver disease are underestimated in clinical practice: impact of a dedicated screening approach at a large university teaching hospital. Diabet Med 2018;35:89-98. [DOI: 10.1111/dme.13540] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
180 Tariq R, Axley P, Singal AK. Extra-Hepatic Manifestations of Nonalcoholic Fatty Liver Disease: A Review. J Clin Exp Hepatol 2020;10:81-7. [PMID: 32025167 DOI: 10.1016/j.jceh.2019.07.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
181 Han E, Cho Y, Kim KW, Lee YH, Kang ES, Cha BS, Lee BW. Hepatic fibrosis is associated with total proteinuria in Korean patients with type 2 diabetes. Medicine (Baltimore) 2020;99:e21038. [PMID: 32871978 DOI: 10.1097/MD.0000000000021038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
182 Wijarnpreecha K, Thongprayoon C, Boonpheng B, Panjawatanan P, Sharma K, Ungprasert P, Pungpapong S, Cheungpasitporn W. Nonalcoholic fatty liver disease and albuminuria: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2018;30:986-994. [PMID: 29787418 DOI: 10.1097/meg.0000000000001169] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 3.8] [Reference Citation Analysis]
183 Seo JY, Bae JH, Kwak MS, Yang JI, Chung SJ, Yim JY, Lim SH, Chung GE. The Risk of Colorectal Adenoma in Nonalcoholic or Metabolic-Associated Fatty Liver Disease. Biomedicines 2021;9:1401. [PMID: 34680518 DOI: 10.3390/biomedicines9101401] [Reference Citation Analysis]